US Pharma MarketingAbbVie-allied ADARx aims to go public with 3 drugs in the clinic
ADARx files for a Nasdaq IPO under Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA…
RNA interference company ADARx Pharmaceuticals revealed its intentions to go public in a Friday night SEC filing, trying to take advantage of the industry's IPO momentum.
The San Diego biotech plans to list on the ...
Source: Endpoints News